RE:RE:ONCY pelareorep as a potential bispecific or ADC payload.December 10, 2023 - The strategy of combining an ADC with a PD-1 immunotherapy got a major boost recently from the combination of Seagen and Astellas’ Padcev and Merck’s Keytruda.
Now Bristol Myers Squibb’s Opdivo topped Seagen’s classical Hodgkin lymphoma (cHL) therapy Adcetris in a head-to-head trial, Seagen has trotted out new datasets suggesting the two drugs—a PD-1 inhibitor and an antibody-drug conjugate—hold potential when paired together as part of a combination.
Adcetris, a CD30-targeted ADC, is currently approved by the FDA in frontline advanced-stage cHL alongside a chemo combo called AVD. With the new regimen, Seagen is trying to replace the vinblastine chemo component with Opdivo.
https://www.fiercepharma.com/pharma/seagen-adcetris-and-bristol-opdivo-boost-hopes-another-adc-pd-1-combo